申请人:SYNAPTIC PHARMACEUTICAL CORPORATION
公开号:US20020049239A1
公开(公告)日:2002-04-25
This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
本发明涉及新型的吲哚和苯并噻唑化合物,这些化合物对克隆的人类α2受体具有选择性。本发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外,本发明还包括使用这些化合物降低眼内压、治疗老视、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供了一种药物组合物,其中包括上述定义的化合物的治疗有效量和药学可接受的载体。